189 related articles for article (PubMed ID: 30077739)
1. Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer.
Miller DR; Tzeng CC; Farmer T; Keller ET; Caplan S; Chen YS; Chen YL; Lin MF
Cancer Lett; 2018 Nov; 436():96-108. PubMed ID: 30077739
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
Pilling A; Kim SH; Hwang C
Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379
[TBL] [Abstract][Full Text] [Related]
3. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
[TBL] [Abstract][Full Text] [Related]
4. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
[TBL] [Abstract][Full Text] [Related]
5. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
[TBL] [Abstract][Full Text] [Related]
6. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
7. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
[No Abstract] [Full Text] [Related]
8. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
Park SE; Kim HG; Kim DE; Jung YJ; Kim Y; Jeong SY; Choi EK; Hwang JJ; Kim CS
Invest New Drugs; 2018 Apr; 36(2):195-205. PubMed ID: 29110173
[TBL] [Abstract][Full Text] [Related]
9. p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance.
Miller DR; Ingersoll MA; Chatterjee A; Baker B; Shrishrimal S; Kosmacek EA; Zhu Y; Cheng PW; Oberley-Deegan RE; Lin MF
Free Radic Biol Med; 2019 Aug; 139():24-34. PubMed ID: 31100478
[TBL] [Abstract][Full Text] [Related]
10. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
11. Development of 2-(5,6,7-Trifluoro-1
Leblanc E; Ban F; Cavga AD; Lawn S; Huang CF; Mohan S; Chang MEK; Flory MR; Ghaidi F; Lingadahalli S; Chen G; Yu IPL; Morin H; Lallous N; Gleave ME; Mohammed H; Young RN; Rennie PS; Lack NA; Cherkasov A
J Med Chem; 2021 Oct; 64(20):14968-14982. PubMed ID: 34661404
[TBL] [Abstract][Full Text] [Related]
12. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
[TBL] [Abstract][Full Text] [Related]
13. Targeting NPRL2 to enhance the efficacy of Olaparib in castration-resistant prostate cancer.
Chen X; Chen Z; Zheng B; Tang W
Biochem Biophys Res Commun; 2019 Jan; 508(2):620-625. PubMed ID: 30522863
[TBL] [Abstract][Full Text] [Related]
14. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
Nelius T; Martinez-Marin D; Hirsch J; Miller B; Rinard K; Lopez J; de Riese W; Filleur S
Cell Death Dis; 2014 May; 5(5):e1210. PubMed ID: 24810046
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
Ku S; Lasorsa E; Adelaiye R; Ramakrishnan S; Ellis L; Pili R
PLoS One; 2014; 9(7):e103680. PubMed ID: 25072314
[TBL] [Abstract][Full Text] [Related]
16. KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer.
Sekino Y; Oue N; Shigematsu Y; Ishikawa A; Sakamoto N; Sentani K; Teishima J; Matsubara A; Yasui W
Urol Oncol; 2017 Jan; 35(1):31.e13-31.e20. PubMed ID: 27665358
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
Mout L; Moll JM; Chen M; de Morrée ES; de Ridder CMA; Gibson A; Stuurman D; Aghai A; Erkens-Schulze S; Mathijssen RHJ; Sparreboom A; de Wit R; Lolkema MP; van Weerden WM
Br J Cancer; 2020 Dec; 123(12):1715-1719. PubMed ID: 32989230
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
[TBL] [Abstract][Full Text] [Related]
19. Deubiquitinating enzyme USP33 restrains docetaxel-induced apoptosis via stabilising the phosphatase DUSP1 in prostate cancer.
Guo F; Zhang C; Wang F; Zhang W; Shi X; Zhu Y; Fang Z; Yang B; Sun Y
Cell Death Differ; 2020 Jun; 27(6):1938-1951. PubMed ID: 31857702
[TBL] [Abstract][Full Text] [Related]
20. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]